Taken together, these results demonstrate that 2-APQC is a novel targeted small-molecule SIRT3 activator that alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis, which would shed new light on discovery of a potential drug candidate for HF treatment in the future. Here, SIRT3 is linked to cardiac hypertrophy.